News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
MarketBeat Market update
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
Kyverna Therapeutics (NASDAQ:KYTX) has received a "Moderate Buy" consensus rating from analysts, with an average 12-month price target of $30.00, significantly above its current price of $8.08. Insider ownership has increased, with hedge funds and institutions owning 18.08% of the stock. The company recently …
Kyverna Therapeutics is making significant progress with its autoimmune drug, mivocabtagene autoleucel, showing strong trial results where all 26 patients stopped chronic immunotherapies and most reported improved mobility. The company is pursuing a rolling Biologics License Application, aiming for completion by late 2026 and …
Kyverna Therapeutics (KYTX) announced its Q2 2026 earnings on August 12, 2026, reporting an EPS of -$0.63, beating the consensus estimate by $0.05. The company's earnings are projected to improve from ($2.70) to ($2.62) per share in the upcoming year. The article details Kyverna …
Kyverna Therapeutics (NASDAQ:KYTX) reported a Q2 loss of $0.63 per share, which beat analyst expectations by $0.04. Following the announcement, shares rose 1.6% to $8.02. The company currently holds a "Moderate Buy" consensus rating from analysts with a target price of $30.00.
Kyverna Therapeutics reported a Q2 2026 net loss per share of $(0.63), surpassing analyst expectations and narrowing its year-over-year loss by 35%. The company also received Regenerative Medicine Advanced Therapy (RMAT) designation for miv-cel in non-active secondary progressive multiple sclerosis (naSPMS) and is on …
Kyverna Therapeutics, Inc. has released its earnings summary for the quarter that ended on June 30. The article is a brief announcement indicating the availability of these financial results. Readers can access the full report via TradingView, which provides content from Reuters and other …
Kyverna Therapeutics reported its second quarter 2026 financial results and provided a business update, highlighting significant progress in its miv-cel neuroimmunology franchise. The company received RMAT designation for miv-cel in non-active secondary progressive multiple sclerosis, is on track to complete its rolling BLA submission …
Kyverna Therapeutics announced its second-quarter 2026 financial results and significant pipeline advancements. The FDA granted RMAT designation for miv-cel in non-active secondary progressive multiple sclerosis, bolstering its neuroimmunology indications. The company is also progressing with its rolling BLA for stiff person syndrome, aiming for …
Renaissance Technologies LLC significantly increased its stake in Kyverna Therapeutics, Inc. (NASDAQ:KYTX) by 106.6% in the first quarter, now owning 367,492 shares valued at $3.17 million. This move is part of a broader trend of increased institutional ownership, which now stands at 18.08%. Analysts …
This article provides an earnings forecast for Kyverna Therapeutics Inc (KYTX), detailing analyst ratings, target prices, and historical and projected EPS figures. Based on ratings from 6 analysts, the stock has a "Buy" trend with a target price indicating significant upside. The report also …
Kyverna Therapeutics, Inc. is projected to report a loss of 68 cents per share in its upcoming earnings release. This information comes from a Refinitiv earnings preview. The full article is available through TradingView News, which provides access to content from various news sources …
Kyverna Therapeutics and ElevateBio have signed a commercial manufacturing and supply agreement for miv-cel, Kyverna's autologous CD19-targeting CAR T-cell therapy. This agreement ensures scalable production for potential commercial launch and ongoing clinical supply, especially for stiff person syndrome (SPS) and generalized myasthenia gravis (gMG). …
Kyverna Therapeutics (KYTX) is expected to report its Q2 2026 earnings on Tuesday, August 11th, with analysts forecasting a loss of $0.67 per share. The company previously exceeded estimates with a $0.66-per-share loss. KYTX shares recently traded up 2.9% to $7.73, and the company …
Faruqi & Faruqi, LLP is investigating potential securities claims against Kyverna Therapeutics (NASDAQ: KYTX) on behalf of investors who suffered losses exceeding $50,000 from the company's IPO around February 8, 2024. The investigation centers on allegations that the IPO's registration statement and prospectus contained …
Kyverna Therapeutics and ElevateBio have signed a manufacturing and supply agreement for Kyverna’s experimental CAR T-cell therapy, miv-cel, which is designed to treat generalized myasthenia gravis (gMG). This deal covers both U.S. commercial and global clinical supply as miv-cel is currently undergoing a registrational …
William Blair has reaffirmed its Buy rating for Kyverna Therapeutics (KYTX.US). This indicates a positive outlook from the analyst firm regarding the company's stock performance.
Two analysts have issued bullish sentiments on prominent healthcare stocks: Eli Lilly & Co (LLY) and Kyverna Therapeutics, Inc. (KYTX). Goldman Sachs analyst Asad Haider reiterated a Buy rating for Eli Lilly & Co with a $1283.00 price target, while William Blair's Sami Corwin …
Kyverna Therapeutics, Inc. has signed a commercial manufacturing and supply agreement with ElevateBio, Inc. for miv-cel, its autologous CD19-directed CAR T-cell therapy. This agreement aims to provide flexible and scalable supply for miv-cel's potential launch in stiff person syndrome and generalized myasthenia gravis, as …
Kyverna Therapeutics Inc. and ElevateBio have signed a manufacturing agreement for the U.S. commercial and global clinical supply of miv-cel, an autologous CD19-directed CAR T-cell therapy. This collaboration, spanning three years, has resulted in a high clinical manufacturing success rate for miv-cel. Kyverna aims …
Kyverna Therapeutics and ElevateBio announced a manufacturing and supply agreement for miv-cel, Kyverna’s CAR T-cell therapy, covering U.S. commercial and global clinical supplies. This partnership aims to provide flexible and scalable manufacturing to support Kyverna's potential launches in stiff person syndrome (SPS) and generalized …
This article details the shareholder structure of Kyverna Therapeutics Inc (KYTX), listing major individual shareholders like VV Manager LLC, Westlake Village BioPartners, and GordonMD Global Investments LP, along with their respective proportions. It also breaks down shareholder types, showing investment advisors, venture capital, and …
This article provides an overview of market sentiment for Kyverna Therapeutics (KYTX), including analyst consensus, short interest, options flow, and insider activity. Analysts currently have an "Overweight" consensus rating with an average price target significantly higher than the current price. While options flow indicates …
Kyverna Therapeutics Inc (KYTX) is trading at $7.410, up 1.65%. The company, a clinical-stage biopharmaceutical firm, focuses on developing cell therapies for autoimmune diseases, with its lead candidate KYV-101 in Phase II clinical trials. Analysts currently rate KYTX as a "Buy" with a target …
This article provides a valuation analysis for Kyverna Therapeutics Inc (KYTX), focusing on its PE, PB, and fair value. It includes current stock pricing, market capitalization, and links to financial data and company overview. The content primarily serves as a placeholder for a more …
This article provides details about Kyverna Therapeutics, Inc. (NASDAQ: KYTX) on the TradingView platform, focusing on its financial information, including an overview of its revenue breakdown. It highlights general financial data points like statements, statistics, dividends, earnings, and segment performance. The page appears to …
Wells Fargo has reiterated its Overweight rating on Kyverna Therapeutics (KYTX). This indicates the firm's continued positive outlook on the company's stock performance. The report from Wells Fargo suggests confidence in Kyverna Therapeutics' future prospects.
Kyverna Therapeutics (KYTX) presented at the Jefferies Global Healthcare Conference 2026, highlighting its leadership in autologous CAR T therapies for autoimmune diseases, particularly focusing on Stiff Person Syndrome (SPS) and Myasthenia Gravis (MG). The company discussed impressive clinical data from over 100 patients, showing …
Kyverna Therapeutics (NASDAQ:KYTX) has received a consensus "Moderate Buy" rating from analysts, with an average twelve-month price target of $30.00. While five analysts recommend buying and one recommends selling, institutional investors have been actively adjusting their positions. The company recently reported better-than-expected earnings, topping …
Kyverna Therapeutics (KYTX) provided an update at the Wells Fargo 20th Annual Healthcare Conference 2025, detailing progress on its lead program KYV-101 for stiff person syndrome (SPS) and myasthenia gravis (MG). KYV-101 is a CD28 co-stimulatory domain, fully human CAR T therapy targeting autoimmune …
This article provides an update on Vaxart, Aphaia, Connect Biopharma, Kyverna, and Chugai, detailing their progress and future milestones discussed at the BIO 2026 conference. It highlights key developments from these biopharmaceutical companies.
Search by ticker symbol or company name and select a result to open its chart.